Centessa Pharmaceuticals (CNTA) Operating Income (2020 - 2026)
Centessa Pharmaceuticals (CNTA) reported Operating Income of -$79.8 million for Q1 2026, down 159.2% year-over-year from $134.8 million in Q1 2025, and down 16.5% quarter-over-quarter from -$68.5 million in Q4 2025.
Centessa Pharmaceuticals (CNTA) Operating Income (2020 - 2026) Analysis & Trends
Centessa Pharmaceuticals (CNTA) has 7 years of Operating Income data on file, last reported at -$79.8 million in Q1 2026.
- Operating Income for Q1 2026 came in at -$79.8 million, down 159.2% year-over-year; the trailing twelve-month figure through Mar 2026 was -$256.7 million (down 31.14% YoY), and the FY2025 annual result was -$207.7 million, down 3.3% from the prior year.
- Operating Income fell to -$79.8 million in Q1 2026 per CNTA's latest filing, from -$68.5 million in the prior quarter.
- Over five years, Operating Income peaked at -$30.8 million in Q1 2025 and troughed at -$79.8 million in Q1 2026.
- A 5-year average of -$51.3 million and a median of -$48.9 million in 2023 frame the typical range for Operating Income.
- The sharpest annual moves came in 2022 and 2026: Operating Income soared 77.47% in 2022, then sank 159.2% in 2026.
- A 5-year view of Operating Income shows it stood at -$41.6 million in 2022, then grew by 15.44% to -$35.2 million in 2023, then slumped by 112.01% to -$74.6 million in 2024, then rose by 8.19% to -$68.5 million in 2025, then retreated by 16.5% to -$79.8 million in 2026.
- Business Quant data shows CNTA's Operating Income at -$79.8 million in Q1 2026, -$68.5 million in Q4 2025, and -$53.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Centessa Pharmaceuticals | 6.15 Bn | 6.15 Bn | - | -79.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -79.77 Mn |
| Dec 31, 2025 | -68.47 Mn |
| Sep 30, 2025 | -53.79 Mn |
| Jun 30, 2025 | -54.65 Mn |
| Mar 31, 2025 | -30.78 Mn |
| Dec 31, 2024 | -74.58 Mn |
| Sep 30, 2024 | -46.41 Mn |
| Jun 30, 2024 | -43.98 Mn |
| Mar 31, 2024 | -36.09 Mn |
| Dec 31, 2023 | -35.18 Mn |
| Sep 30, 2023 | -40.21 Mn |
| Jun 30, 2023 | -47.02 Mn |
| Mar 31, 2023 | -48.88 Mn |
| Dec 31, 2022 | -41.60 Mn |
| Sep 30, 2022 | -49.03 Mn |
| Jun 30, 2022 | -68.41 Mn |
| Mar 31, 2022 | -53.22 Mn |
| Dec 31, 2021 | -58.29 Mn |
| Sep 30, 2021 | -38.31 Mn |
| Jun 30, 2021 | -41.29 Mn |